CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

NDA 20193/S-002

Trade Name: ELMIRON

Generic Name: Pentosan Polysulfate Sodium

Sponsor: JANSSEN PHARMS

Approval Date: 11/08/2001

Indications: ELMIRON is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative indicated for:

- the relief of pain or discomfort associated with interstitial cystitis.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 20193/S-002

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Approvable Letter	
Labeling	
Summary Review	
Officer/Employee List	
Office Director Memo	
Cross Discipline Team Leader Review	
Medical Review(s)	
Chemistry Review(s)	**X**
Environmental Assessment	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	
Other Review(s)	
Administrative/Correspondence Document(s)	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 20193/S-002

APPROVAL LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-193/S-002

Alza Corporation
Attention: Elizabeth (Betty) Clark
Director, Regulatory Affairs
1900 Charleston Road
P. O. Box 7210
Mountain View, CA 94039-7210

Dear Ms. Clark:

Please refer to your supplemental new drug application dated July 23, 2001, received July 24, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Elmiron® (pentosan polysulfate sodium) Capsules, 100 mg.

We acknowledge receipt of your submission dated August 17, October 24, and October 25, 2001.

This "Changes Being Effected" supplemental new drug application provides for the removal of the cotton filler from the HDPE bottles used to package Elmiron® Capsules.

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Evelyn R. Farinas, R.Ph., M.G.A., Regulatory Project Manager, at (301) 827-4260.

Sincerely,

{See appended electronic signature page}

David Lin, Ph.D.
Chemistry Team Leader for the
Division of Reproductive and Urologic Drug Products,
(HFD-580)
Division of New Drug Chemistry II
Office of New Drug Chemistry
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David T. Lin
11/8/01 12:47:27 PM
I concur.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 20193/S-002

CHEMISTRY REVIEW(S)

CHEMIST REVIEW
OF SUPPLEMENT

1. ORGANIZATION: CDER/HFD-580 Division of Reproductive and Urologic Drug Products

2. NDA NUMBER: 20-193

3. SUPPLEMENT NUMBERS/DATES: SCS-002

Letter date: July 23, 2001
Stamp date: July 24, 2001

4. AMENDMENTS/REPORTS/DATES:

Letter date: August 17, 2001
Stamp date: August 20, 2001
Letter date: October 24, 2001
Stamp date: October 25, 2001
Letter date: October 24, 2001
Stamp date: October 26, 2001

5. RECEIVED BY CHEMIST: July 24, 2001

6. APPLICANT NAME AND ADDRESS:

ALZA Corporation
1900 Charleston Road
P.O. Box 7210
Mountain View, CA 94039-7210

7. NAME OF DRUG: Elmiron® Capsule

8. NONPROPRIETARY NAME: Pentosan polysulfate sodium

9. CHEMICAL NAME/STRUCTURE:



10. DOSAGE FORM(S): Oral Capsule

11. POTENCY: 100mg

12. PHARMACOLOGICAL CATEGORY: Non-steroidal anti-inflammatory agent for the treatment of interstitial cystitis

13. HOW DISPENSED: Rx

14. RELATED IND/NDA/DMF: DMF # (b) (4)

15. SUPPLEMENT PROVIDES FOR: Removal of the cotton filler from the HDPE bottles used to package Elmiron® capsules. The amendment of August 17, 2001 is for the replacement of the innerseal. The amendment of October 24, 2001 is for submission of the authorization letter to (b) (4)

16. COMMENTS:
See review notes.

17. CONCLUSIONS AND RECOMMENDATIONS: This CBE supplement may be approved. Issue approval letter.

18. REVIEWER NAME **SIGNATURE** **DATE COMPLETED**
Jila Boal, Ph. D.

cc: Original: Division File NDA 20-193/SCS-002
HFD-580/JBoal/DLin/EFarinas
INIT: by D Lin

2 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

---

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Jila Boal
10/30/01 04:30:58 PM
CHEMIST

David T. Lin
10/30/01 04:41:02 PM
CHEMIST
I concur.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 20193/S-002

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

Teleconference Minutes

Date: October 19, 2001 **Time:** 3:00-3:15 PM, EST **Location:** PKLN; 13B45

NDA 20-193 **Drug:** Elmiron® **Indication:** interstitial cystitis

Sponsor: Alza Corporation

Type of Meeting: Clarification

Meeting Chair: Jila Boal, Ph.D., Chemist, Division of New Drug Chemistry II (DNDC II) @ Division of Urologic and Reproductive Drugs (DRUDP; HFD 580)

External Lead: Peter Quigley, Regulatory Affairs, Alza Corporation

Meeting Recorder: Evelyn R. Farinas, R.Ph., M.G.A., Regulatory Project Manager, DRUDP (HFD-580)

FDA Attendees:
Jila Boal, Ph.D. - Chemist, DNDC II @ DRUDP (HFD 580)
Evelyn R. Farinas, R.Ph., M.G.A. – Regulatory Project Manager, DRUDP (HFD-580)

External Attendees:
Peter Quigley - Regulatory Affairs Associate, Alza Corporation
Betty Clark – Director, Regulatory Affairs, Alza Corporation
Rebecca Tarlow – Manager, Quality Assurance, Alza Corporation
(b) (6)

Meeting Objective: To obtain clarification if the inside of the white opaque child resistant cap (b) (4) is also coated with the liner/inner seal material that is mentioned in the amendment of August 17, 2001.

Background: On July 23, 2001, the sponsor submitted a Changes Being Effected supplement (S002) informing the Agency of the removal of the cotton filler from the HDPE bottles used to package Elmiron® capsules. Subsequently, on August 17, 2001, Alza submitted an amendment to S002 indicating that the inner seal would be replaced.

Discussion:

- regarding the inner seal, the sponsor indicated that:
  - the proposed inner seal had not been used by Alza previously; however, the proposed inner seal was used commonly in industry
  - the liner was an innovation for this product, but the outer shell remained unchanged
  - (b) (4)
  - (b) (4)

- DRUDP stated that the induction seal at the mouth of the bottle was adequate
- DRUDP requested that the sponsor submit a Letter of Authorization to allow review of (b) (4)

Decisions made:

- DRUDP to review (b) (4) prior to finalizing review of the July 23, and August 17, 2001, submissions

Action Items:

- the sponsor will submit a Letter of Authorization for (b) (4)
- minutes of this teleconference will be sent to the sponsor within 30 days

Note to sponsor: These minutes are the official minutes of the meeting. You are responsible for notifying us of any significant differences in understanding you may have regarding the meeting outcomes.

Drafted: Farinas/October 23, 2001
Concurrence: Rumble 10.23.01/Boal 10.23.01
Finalized: Farinas/10.26.01

MEETING MINUTES

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Evelyn Farinas
10/25/01 03:25:57 PM
CSO

Jila Boal
10/25/01 04:31:56 PM
CHEMIST

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-193/S-002

CBE 0 SUPPLEMENT

Alza Corporation
Attention: Tracy Lin
Manager, Regulatory Affairs
1900 Charleston Road
P.O. Box 7210
Mountain View, CA

Dear Ms. Lin:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Elmiron (pentosan polysulfate sodium) Capsules

NDA Number: 20-193

Supplement Number: S-002

Date of Supplement: July 23, 2001

Date of Receipt: July 24, 2001

This supplemental application, submitted as a "Supplement - Changes Being Effected in 30 days" supplement, proposes the following change: removal of the cotton filer from the HDPE bottles used to package Elmiron capsules.

Unless we notify you within 60 days of our receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on September 22, 2001 in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be January 24, 2002.

Please cite the application number listed above at the top of the first page of any communications concerning this application. All communications concerning this supplemental application should be addressed as follows:

U.S. Postal/Courier/Overnight Mail:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Reproductive and Urologic Drug Products, HFD-580
Attention: Division Document Room
5600 Fishers Lane
Rockville, Maryland 20857

If you have any questions, call Evelyn R. Farinas, R.Ph., M.G.A., Regulatory Project Manager, at (301) 827-4260.

Sincerely,

{See appended electronic signature page}

Terri Rumble
Chief, Project Management Staff
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Terri F. Rumble

8/1/01 10:03:53 AM